Cargando…
HER2-Targeted Antibody–Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget’s Disease Models: In Vivo and Immunohistochemical Analyses
SIMPLE SUMMARY: The prognosis for advanced Extramammary Paget’s disease (EMPD) is almost always poor. HER2-targeted antibody–drug conjugates (ADCs) such as trastuzumab emtansine and trastuzumab deruxtecan have proven to be effective against HER2-positive breast cancers; however, no studies have addr...
Autores principales: | Tokuchi, Keiko, Maeda, Takuya, Kitamura, Shinya, Yanagi, Teruki, Ujiie, Hideyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322551/ https://www.ncbi.nlm.nih.gov/pubmed/35884581 http://dx.doi.org/10.3390/cancers14143519 |
Ejemplares similares
-
Cyclin‐dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget’s disease
por: Kitamura, Shinya, et al.
Publicado: (2021) -
Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft
por: Hsu, Che-Yuan, et al.
Publicado: (2023) -
Extramammary Paget’s disease
por: Vasquez, Andres, et al.
Publicado: (2016) -
Potential Use of Bisphosphonates in Invasive Extramammary Paget's Disease: An Immunohistochemical Investigation
por: Fujimura, Taku, et al.
Publicado: (2013) -
Extramammary Perianal Paget's Disease
por: Al Hallak, M.N., et al.
Publicado: (2009)